New Triple-Drug combo shows promise in shrinking breast tumors before surgery
NCT ID NCT02520063
First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tested a combination of three drugs (letrozole, everolimus, and TRC105) given before surgery to postmenopausal women with newly diagnosed, hormone-receptor-positive, HER2-negative breast cancer. The goal was to see if the drugs were safe and could shrink tumors. The study involved 15 participants and found the treatment was tolerable, with the main focus on safety and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.